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ABSTRACT  
Introduction: Spirometry is important in the diagnosis and management of chronic obstructive pulmonary disease (COPD), yet it is a 
common clinical observation that it is underused though the extent is unclear. This survey aims to examine the use of spirometry in the 
diagnosis and management of COPD patients in districts of, Karachi. Material and Methods: It is a cross-sectional survey involving four 
clinic settings: hospital-based respiratory specialist clinic, hospital-based mixed medical specialist clinic, general outpatient clinic 
(primary care), and tuberculosis and chest clinic. Thirty physician-diagnosed COPD patients were randomly selected from each of the 
four clinic groups. All of them had a forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio less than 0.70 and 
had been followed up at the participating clinic for at least 6 months for COPD treatment. Results: Of the 120 COPD patients, there were 
111 males and mean post-bronchodilator FEV1 was 46.2% predicted. Only 22 patients (18.3%) had spirometry done during diagnostic 
workup, and 64 patients (53.3%) had spirometry done ever. Conclusion: We conclude that spirometry is underused in general but 
especially by non-respiratory physicians and family physicians in the management of COPD patients. More effort at educating the medical 
community is urgently needed. 
KEYWORDS: Pulmonary function tests, Specialist, Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC). 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is characterized 
by advancing airflow obstruction and impairment of gaseous 
exchange resulting in progressive worsening of shortness of 
breath. The disease affects 65 million people worldwide and 
more than 12 million people in the US alone, and is it likely that 
these figures are grossly underestimated.[1–3] More than three 
million people died from COPD in 2005, and it is predicted that 
mortality from this disease will continue to increase.[2] In 
Pakistan, the burden of COPD is also high, with high utilization 
of health care resources.[4–6] 
Diagnosis of COPD rests on history, physical examination, 
chest radiograph, and the demonstration of airflow obstruction 
by spirometry. Although being criticized as overly simplistic,[7,8] 
the spirometric finding of a post-bronchodilator forced 
expiratory volume in 1 second (FEV1) to forced vital capacity 
(FVC) ratio of less than 0.70 is still universally accepted as 
being diagnostic of significant airflow obstruction.[1, 9–11] Having 
made the diagnosis, one would like to assess the severity of the 
disease. Percentage predicted post-bronchodilator FEV1 is 
objective and reproducible, correlates well with disease severity, 
and is a good prognostic indicator.[12, 13] Furthermore, in the 
subsequent management of COPD, serial FEV1 can serve to 
follow the progress of the disease and provide guidance on 
treatment options in different stages of disease evolution. 
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It is therefore hardly surprising that all the major international 
COPD management guidelines mandate the use of spirometry in 
the initial diagnostic evaluation of patients with symptoms 
suggestive of COPD.[1,10,11,14] However, it is a common 
observation in daily clinical practice that spirometry is very 
much underused. In fact, it is not uncommon for patients with 
severe COPD to have the disease diagnosed and treated for 
many years, yet have no spirometry done. To examine the extent 
of the problem, we set out to conduct a survey to observe the use 
of spirometry in COPD management. 
MATERIALS AND METHODS 
The objective of the survey was to observe what investigations 
and treatments COPD patients actually receive 
This is a cross-sectional survey carried out in Lyari and Garden 
areas of Karachi, with a population of approximately 616,151. 
There were a total of eleven secondary level clinics or health 
centers in the private and public sector which care for COPD 
patients in the area under study. COPD patients had long-term 
follow-up. The clinics or health centers were grouped according 
to their specialty, and 30 COPD subjects were selected from 
each group: group 1, one respiratory specialist clinic or health 
center; group 2, four general medical specialist clinics or health 
centers; group 3, five family medicine clinics or health centers 
or general outpatient clinics or health centers (primary care 
clinics); group 4, one tuberculosis and chest clinics or health 
centers. 
For groups 1–3, subject lists were generated from the hospital 
Data Analysis and Reporting System in June 2014. Subjects 
were randomly selected from the list and were invited to 
participate in the study by phone call. An appointment was given 
to verbally consenting subjects to attend a study visit. 
Recruitment for each group stopped when 30 consenting and 
evaluable subjects for that group has been accrued. For group 4, 
since no patient list could be generated, COPD subjects were 
invited to participate in the study as they attended follow-up at 
the clinic; workflow was similar to the other groups. 
At the study visit, subjects signed an informed consent form and 
were then checked for study entry criteria. Inclusion criteria 
were: (1) physician-diagnosed COPD, (2) post-bronchodilator 
FEV1to FVC ratio less than 0.70 (3) regular follow-up at the 
participating clinic for treatment of stable COPD for at least 6 
months, and (4) willing and able to comply with study 
requirements such as performing spirometry and 6-minute walk 
test. Exclusion criteria were: (1) non-COPD diagnosis as judged 
by the investigator; (2) subjects attending regular follow-up at 
another clinic and attending the participating clinic irregularly 
for acute exacerbation of COPD or other problems; (3) history 
of significant coexisting chronic lung disease such as asthma, 
pulmonary fibrosis, bronchiectasis, and restrictive lung disease; 
and (4) history of lung resection. 
When the subjects satisfied all inclusion and none of the 
exclusion criteria, collection of demographic data, medical data, 
and smoking history was done. The use of spirometry in the 
diagnosis and subsequent management of COPD were recorded 
from the medical records and word of mouth was not accepted. 
Use of spirometry for diagnostic workup is defined as 
spirometry done within 6 months before or after making the 
COPD diagnosis. If the subject had spirometry done in the study 
center within the previous year, the result was used for study 
analysis, otherwise spirometry was done for all subjects during 
the study visit. This was done according to American Thoracic 
Society/European Respiratory Society 2012 
recommendations,[15] and the subject must not have had COPD 
exacerbation in the preceding four weeks. Local reference 
values were used for FEV1 and other spirometric parameters.
[16] 
Measurement of body mass index; 6-minute walking distance,[17] 
and dyspnea level using the Medical Research Council dyspnea 
scale[18] were also done. 
After the study visit, subjects continued to attend regular follow-
up at their original clinic. Summaries of a subject’s clinical 
findings and/or treatment recommendations were supplied to the 
care giver on request. 
Data were expressed as percentages, means, and medians, as 
appropriate. During univariate analysis to compare variables 
between the groups with and without spirometry ever 
performed, independent-samples t-test, Mann–Whitney U-test, 
and chi-square test were used as appropriate. If there was at least 
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one group with expected count less than 5 when comparing 
distributions, Fisher’s exact test was used. McNemar’s test was 
used to compare the proportion of patients with spirometry 
and/or chest radiograph done at diagnosis/ever because the 
samples were deemed related. With the same standpoint, mean 
time before study visit of spirometry and chest X-ray were 
compared by t-test for two related samples. Those variables with 
P-value less than 0.2 in univariate analysis were subject to 
logistic regression by backward elimination method, with 
“significant level of stay” set to 0.10. A P-value of less than 0.05 
was considered statistically significant. 
The study was approved by the Research Ethics Committee of 
Shaheed Mohtarma Benazir Bhutto medical college Karachi and 
the Ethics Committee of the Department of Health. 
RESULTS 
Subject recruitment started in June 2014 and was completed in 
November 2014. A total of 144 subjects were invited to 
participate in the study. Fourteen subjects refused to participate; 
two were excluded because of concomitant lung disease, and 
one died before attending a study visit. The remaining 127 
subjects attended study visits. Seven were excluded because the 
diagnosis was judged to be non-COPD on basis of spirometry. 
Finally, the data of 120 subjects with 30 from each clinic group 
were analyzed (Table 1). 
For the six subjects who were excluded during study visits for 
non-COPD diagnosis, all had a FEV1 to FVC ratio greater than 
0.70, and five had a post-bronchodilator FEV1 percentage 
predicted higher than 80%. Three had chronic bronchitic 
symptoms and were given the diagnosis of “bronchitis not 
otherwise specified,” one had mild bronchiectasis, which could 
explain the symptom of chronic productive cough, while one 
had no bronchitic symptoms and was considered free from lung 
disease. The remaining female subject had a very low post-
bronchodilator FEV1 of only 40% predicted, and she likely 
suffered from interstitial lung disease. 
For the final 120 subjects, males predominated (111, 92.5%), 
and mean age was 71.8 years. All were local residents and all 
but six were either current or ex-smokers. Mean post-
bronchodilator FEV1 was 46.2% predicted, and stratification 
into Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stages1 was: stage I, 10 (8.3%); stage II, 38 (31.7%); 
stage III, 46 (38.3%); and stage IV, 26 (21.7%). Other 
characteristics are shown in Table 2 & 3.
Table: 1. Subject Screening and Recruitment Summary 
n: Number of patientsFEV1: Forced expiratory volume in first second, FVC: Forced vital capacity. 
Total No of Patients 
(n=144) 
GROUP 1 
Respiratory Specialist 
Clinics 
(n=37) 
GROUP 2 
General Medical 
Clinics 
(n=35) 
GROUP 3 
General Out 
Patient Clinics 
(n=37) 
GROUP 3 
Tuberculosis and 
Chest Clinics 
(n=35) 
No of Patients attended the study 
(n=127) 
 
30 
 
32 
 
34 
 
31 
No of Patients refused to attended the study 
(n=17) 
 
7 
 
3 
 
3 
 
4 
No of Patients excluded on basis of 
spirometry (FEV1/FVC=>0.80%) (n=7) 
Nil 2 4 1 
No of patients finally attended the study 
(n=120)           30 30 30 30 
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Table 2.  Subject characteristics according to whether spirometry was ever performed 
PARAMETER ALL (n=120) 
WITH 
SPIROMETERY 
(n=64) 
WITHOUT 
SPIROMETERY 
(n=56) 
p-Value 
Male : Female 111 : 9 58 : 6 53 : 3 ------- 
Male % 92.5% 90.6% 94.6% 0.500a 
Age (mean, SD) 71.8 (8.02) 71.7 (7.04) 71.9 (8.82) 0.883b 
SMOKING 
STATUS: 
Never (n, %) 
Ex (n, %) 
Current (n, %) 
Pack / Year( mean, 
SD) 
 
 
6(5%) 
88(73.3%) 
26(21.7%) 
58.4(37.90%) 
 
 
4(6.3%) 
48(75.0%) 
12(18.8%) 
59.2(36.46%) 
 
 
2(3.6%) 
40(71.4%) 
14(25%) 
57.6(39.45%) 
 
 
---- 
---- 
0.407c 
0.226d 
Worker occupation 
(n, %) 
70(58.3%) 38(59.4%) 32(57.1%) 0.805c 
With old PTB (n, %) 20(16.7%) 5(7.6%) 15(26.8%) 0.005c 
e Significant Medical 
Morbidity 
At least one (n, %) 
 
 
 
72(60.0%) 
 
 
 
38(59.4%) 
 
 
 
34(60.7%) 
 
 
 
0.881c 
Duration of COPD in 
years (mean, SD) 
9.8 (7.55) 9.6 (6.18) 10.1 (8.86) 0.431d 
Post BD FEV1 %age 
predicted (mean/SD) 
46.2 (19.89) 41.0 (17.57) 52.1 (20.72) 0.022d 
Post BD FVC %age 
predicted (mean/SD) 
71.7 (22.86) 66.6 (26.62) 77.5 (24.07) 0.027d 
Peak expiratory ratio 
(FEV1/FVC) (mean/ 
SD) 
0.476 (0.131) 0.455 (0.126) 0.499 (0.133) 0.067d 
FEV1 BD reversablity (mean, SD) 
Volume Change (ml) 122.5 (124.1) 104.8 (113.9) 142.7 (133.0) 0.145d 
Percentage change 5.5 (5.5) 4.8 (5.0) 6.4 (5.9) 0.137d 
a Fischer`s exact test,bIndependent sample t-test, c Chi square test, d Mann-Whitney U test, e 
Significant medical comorbidity includes hypertension, ischemic heart disease, congestive heart failure, cardiac arrhythmia, 
cerebrovascular disease, diabetes mellitus with or without complications, chronic liver disease, chronic renal disease, obstructive 
sleep apnea, rheumatoid arthritis, tumors, malignancies, depression, and schizophrenia.SD, standard deviation; PTB, pulmonary 
tuberculosis; COPD, chronic obstructive pulmonary disease; post-BD, post-bronchodilator; FEV1, forced expiratory volume in 
1 second; FVC, forced vital capacity; 
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Table 3. Subject characteristics according to whether spirometry was ever performed 
PARAMETER ALL (n=120) WITH 
SPIROMETERY 
(n=64) 
WITHOUT 
SPIROMETERY 
(n=56) 
p-Value 
 
 
GOLD Stage (n, % of group, 95% CI) 
Stage I 10 2(20%, 4.8-44.8%) 08 (80%)  
 
 
 
0.003a 
Stage II 38 15(39.5%, 24-55%) 23(60.5%) 
Stage III 46 27(58.7%, 44.5-
72.9%) 
19(41.3%) 
Stage IV 26 20(76.9%, 60.7-
93.1%) 
06(23.1%) 
BMI (mean, SD) 22.2(3.84) 22.4(3.56) 22.1(4.13) 0.479d 
6 MWD in meters 
(median, SD) 
253.7(77.20) 256.7(77.53) 250.2(76.68) 0.650b 
MRC dyspnea score 
(median, IQR)   
2(1) 2(1) 2(1) 0.941d 
Fischer`s exact test, bIndependent sample t-test, c Chi square test, d Mann-Whitney U test, 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index; 6 MWD, 6-minute walking distance; 
MRC, Medical Research Council; CI, confidence interval; IQR, interquartile range. 
CLINIC LOCATION 
Respiratory 
Specialist Clinic 
(group 1) 
30 29(96.7%) 1(3.3%) 0.000c 
Medical Specialist 
Clinic (group 2) 
30 20(66.7%) 10(33.3%)  
Primary Care Clinic  
(group 3) 
30 08(26.7%) 22(73.3%)  
Tuberculosis and 
Chest Clinic  
(group 4) 
30 07(23.3%) 23(76.7%)  
Group 2+3+4 90 35(38.9%) 55(61.1%)  
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Table 4. Factors associated with spirometry ever done – multivariate analysis (logistic regression by backward elimination). 
PARAMETERS ADJUSTED ODD`S RATIO 95% CI P -Value 
With old PTB 0.138 (0.026-0.726) 0.019 
Clinical locations (compared with group 1) 
Group 2 0.049 (0.005-0.4720 0.009 
Group 3 0.009 (0.001-0.092) 0.000 
Group 4 0.008 (0.001-0.080) 0.000 
GOLD stage (compared with 
stage 1) 
  NS 
Post BD FEV1   NS 
%age predicted post BD FVC   NS 
%age predicted peak 
expiratory ratio (FEV1/FVC) 
  NS 
FEV1 BD reversibility change 
(ml) 
  NS 
FEV1 BD reversality change 
(%) 
  NS 
CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; post-BD, post-bronchodilator; FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity; NS, non-significant.
Table 5. Comparison of use of spirometry and chest radiograph 
PARAMETERS SPIROMETRY CHEST RADIOGRAPH Pvalue 
Done at Diagnosis 22 (18.3%) 96 (80%) 0.000a 
Done Ever 64 (53.3%) 117 (97.5%) 0.000b 
Mean time before study 39.1 12.1 0.000b 
Visit (months) - - - 
Range (months) 1 - 132 0.5 - 84.0 NA 
aMcNemar’s test; bt-test for two related samples; NA , not applicable. 
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Sixty-four subjects (53.3%) had spirometry ever done prior to 
study visit and 56 subjects did not. Table 2 and 3 presents data 
comparing demographic and medical data of the two groups. By 
univariate analysis, factors significantly associated with 
spirometry ever done were absence of old pulmonary 
tuberculosis, more severe disease (lower post-bronchodilator 
FEV1 percentage predicted and more severe GOLD stage), post-
bronchodilator FVC percentage predicted, and clinic group 1 
(versus groups 2, 3, and 4 combined). All other factors did not 
show statistically significant differences between the two 
groups. These include age, sex, smoking status, number of pack-
years, former worker occupation, presence of significant 
comorbidities, duration of COPD, body mass index, exercise 
capacity (6-minute walking distance), and severity of dyspnea 
(Medical Research Council dyspnea score). 
In the subsequent multivariate analysis (Table 4), absence of old 
pulmonary tuberculosis and clinic group 1 significantly favored 
spirometry ever done, whereas GOLD stage, post-
bronchodilator FEV1 percentage predicted, post- bronchodilator 
FVC percentage predicted, peak expiratory ratio (FEV1/FVC), 
and FEV1 bronchodilator reversibility change in volume and 
percentage were not. 
Table 5 shows the use of spirometry compared with chest 
radiograph, which is another important investigation in the 
management of COPD. Overall, spirometry was performed in 
only 22 subjects (18.3%) during diagnostic workup, and 64 
subjects (53.3%) had it ever done. For those who had spirometry 
ever done the mean time interval before study visit was 39.1 
months, with a range of 1–132 months. By contrast, chest 
radiograph was done at diagnostic workup in 96 subjects (80%) 
and was ever done in 117 subjects (97.5%). Mean time of last 
order of chest radiograph prior to study visit was much shorter 
at 12.1 months, with a range of 0.5–84.0 months. All the 
differences were highly statistically significant. 
The timeframe of performing spirometry prior to study visit is 
depicted in Graph 1. The Graph shows that at all time points, 
group 1 had a higher proportion of patients having spirometry 
performed compared with the other groups. Of note is that 
within 2 years preceding the study visit, 21 subjects (70%) in 
group 1 had spirometry done, whereas values for groups 2, 3, 
and 4 were 6 (20%), 3 (10%) and 1 (3.3%) respectively. 
 
DISCUSSION  
To our knowledge this is the first cross-sectional survey to 
examine the use of spirometry in the management of diagnosed 
COPD patients in Karachi. Our data shows that only 18.3% of 
COPD patients invarious districts had spirometry done at 
diagnosis and 53.3% had it ever done, indicatinginconsistent 
use. Interestingly, this problem appears to be commonplace 
across the world.A Swedish survey found that of 533 newly 
diagnosed COPD patients, 59% had spirometry performed and 
45% had post bronchodilator spirometry values. An FEV1 to 
FVC ratio of less that 0.70 was found in only 30% of patients.[19] 
The Canadian CAGE study involving 1,090 COPD patients 
from Quebec and Ontario found that 56% had spirometry ever 
done.[20] In the People’s Republic of China, a large survey 
involving 20,245 COPD subjects from seven provinces/cities 
showed that only 6.5% were tested with spirometry.[21] A recent 
audit of the US Veterans Health Administration involving 
93,724 newly diagnosed COPD patients found that only 36.7% 
had spirometry performed 2 years before or 6 months after the 
diagnosis was made.22 This was despite the (then) recent 
inclusion of this investigation as a performance measure by the 
United States National Committee for Quality Assurance.[22] 
When we tried to look for factors that favor performance of 
spirometry, we found as expected that clinic location is the most 
important factor. This finding suggests that patient factors were 
not responsible for alerting a doctor to order spirometry in 
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COPD management. Rather, the medical specialty appear to be 
the important factor, with respiratory physicians most inclined 
to order spirometry followed by general physicians followed by 
primary care physicians and tuberculosis and chest physicians. 
Similar findings were reported by Lee et al, [23] in which use of 
spirometry for newly diagnosed COPD patients was 3.3 times 
higher for those visiting pulmonologists compared with those 
visiting primary care alone. One possible explanation for these 
findings is that patients followed up at respiratory specialist 
clinics have more severe disease, but statistical analysis of our 
data has indicated that disease severity is not an important factor 
in this regard.A more plausible explanation might be that 
specialization towards respiratory medicine increases awareness 
of the need for spirometry and the proficiency in interpreting the 
spirometry results. Overseas surveys have observed that use of 
office spirometry is associated with many practical problems, 
including availability of spirometer and space, need for 
calibration and standardization of the spirometer,[24] and 
availability of adequately trained staff.[25] Confidence in 
interpretive skills appears to be an important factor in primary 
care[26] and was not improved by computerized expert report 
systems.[27] Chest radiograph on the other hand is readily 
available and routinely reported by radiologists, and its higher 
utilization compared with spirometry may lend support to the 
above speculation. 
A surprise finding is the significant association of the presence 
of old pulmonary tuberculosis with lack of spirometric 
assessment. There have not been similar reports elsewhere, and 
the cause for this finding is not immediately obvious. One would 
have thought that old pulmonary tuberculosis should be an 
additional prompt for doctors to order spirometry since there is 
another lung pathology on top of COPD. However, if doctors 
can ignore factors like smoking status, significant dyspnea, and 
poor exercise tolerance, old pulmonary tuberculosis as a prompt 
to order spirometry may not be a realistic expectation. 
Damarla et al[28] reported in a retrospective study that of patients 
admitted to hospital over an 8-year period, only 31% of COPD 
patients (36% with concomitant respiratory failure) had 
spirometry done, whereas 78% had two-dimensional 
echocardiography done for patients with congestive heart 
failure. For the 219 patients with both conditions, 48% had two-
dimensional echocardiography as the onlyconfirmatory test, 
34% had both tests performed, and only 2% had spirometry 
alone. The result is disturbing, since the two tests are very 
comparable in availability, complexity, ease of interpretation, 
and utility for treatment guidance. These findings once again 
suggest that physicians are insufficiently informed on the 
importance of spirometry in COPD management. 
It would appear then that educational workshops with 
information on the indications, interpretation, and implications 
of spirometry results, and hands on workshops on lung function 
testing may contribute towards solving the current problem. 
Some published reports focusing on primary care show good 
short-term results,[29, 30] but longer-term improvements remain to 
be seen. Published reports on spirometry workshops with a 
wider medical audience are lacking. On a different front, 
spirometry campaigns such as the 2010 World COPD and 
Spirometry Day may also be useful in increasing public 
awareness, putting pressure on the medical community to use 
the test appropriately and consistently. Finally, the setting up of 
incentive systems like the Quality and Outcomes Framework for 
general practitioners in the United Kingdom is likely to be 
helpful. 
Our study has the strength that subjects are enrolled from 
different clinic types, which allows comparisons between them. 
Also, unlike surveys based on diagnostic and procedural coding, 
all of our subjects attended a study visit and had clinical and 
spirometry assessment done to confirm the diagnosis of COPD 
and whether spirometry was done. 
Previously the study is however limited by its relatively small 
sample size and its limited location in Garden/Lyari. Larger, 
territory-wide studies would be able to give more precise 
information on the overall situation. Another limitation is the 
small proportion of female subjects, which probably reflects the 
low prevalence of smoking amongst women and which severely 
limits the applicability of our results to this gender. 
CONCLUSION 
In conclusion, spirometry is inconsistently used in the 
management of COPD in Garden/Lyari region,Karachi, with 
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most of the problem being seen in non-respiratory and primary 
care clinics. A combination of monitoring systems on the use of 
spirometry in COPD, more education on the importance of 
spirometry in COPD management, and assistance in 
interpretation of spirometry results may bring about 
improvements. 
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